Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies

Tissue Antigens

Volumn 81, Issue 4, 2013, Pages 183-193

  Warren, E H ^a,b   Deeg, H J ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adoptive immunotherapy; Conditioning regimen; Graft versus host disease; Graft versus leukemia

Indexed keywords

CD40 LIGAND; CYCLOSPORIN; GLUCURONOSYLTRANSFERASE 2B7; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DRB1 ANTIGEN; INTERLEUKIN 2; IPILIMUMAB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE SEVERITY; DONOR LYMPHOCYTE INFUSION; DONOR SELECTION; EFFECTOR CELL; GENOTYPE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; MYELOID LEUKEMIA; NATURAL KILLER CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; TUMOR IMMUNITY; VACCINATION; WHOLE BODY RADIATION;

CHROMOSOME MAPPING; GENETIC LOCI; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84875524917     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12090     Document Type: Review

References (80)

1. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979: 300: 1068-73.
2. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981: 304: 1529-33.
3. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990: 75: 555-62.
4. Gratwohl A, Brand R, Apperley J et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002: 100: 3877-86.
5. Stern M, de Wreede LC, Brand R et al. Impact of graft-versus-host disease on relapse after allogeneic hematopoietic stem cell transplantation, an EBMT megafile study. ASH Annual Meeting Abstracts 2012: 120: 469.
6. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002: 295: 2097-100.
7. Ruggeri L, Mancusi A, Capanni M et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007.
8. Vago L, Perna SK, Zanussi M et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009: 361: 478-88.
9. Villalobos IB, Takahashi Y, Akatsuka Y et al. Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation. Blood 2010: 115: 3158-61.
10. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005: 366: 733-41.
11. Zorn E, Wang KS, Hochberg EP et al. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res 2002: 8: 2052-60.
12. Kircher B, Stevanovic S, Urbanek M et al. Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br J Haematol 2002: 117: 935-9.
13. Marijt WA, Heemskerk MH, Kloosterboer FM et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A 2003: 100: 2742-7.
14. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995: 86: 4337-43.
15. Alyea EP, Soiffer RJ, Canning C et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998: 91: 3671-80.
16. Takami A, Sugimori C, Feng X et al. Expansion and activation of minor histocompatibility antigen HY-specific T cells associated with graft-versus-leukemia response. Bone Marrow Transplant 2004: 34: 703-9.
17. den Haan JM, Meadows LM, Wang W et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998: 279: 1054-7.
18. Brickner AG, Warren EH, Caldwell JA et al. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J Exp Med 2001: 193: 195-206.
19. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010: 467: 1061-73.
20. Warren EH, Zhang XC, Li S et al. Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. Blood 2012: 120: 2796-806.
21. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003: 197: 1279-89.
22. Molldrem JJ, Lee PP, Wang C et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000: 6: 1018-23.
23. Rezvani K, Yong AS, Savani BN et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes following allogeneic stem cell transplantation for acute lymphoblastic leukemia (ALL). Blood 2007: 110: 1924-32.
24. Atanackovic D, Arfsten J, Cao Y et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007: 109: 1103-12.
25. McLarnon A, Piper KP, Goodyear OC et al. CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect. Haematologica 2010: 95: 1572-8.
26. Takahashi Y, Harashima N, Kajigaya S et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest 2008: 118: 1099-109.
27. Verheyden S, Schots R, Duquet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005: 19: 1446-51.
28. Hsu KC, Keever-Taylor CA, Wilton A et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005: 105: 4878-84.
29. Stringaris K, Adams S, Uribe M et al. Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLA-identical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant 2010: 16: 1257-64.
30. Hsu KC, Gooley T, Malkki M et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006: 12: 828-36.
31. Miller JS, Cooley S, Parham P et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007: 109: 5058-61.
32. Cooley S, Trachtenberg E, Bergemann TL et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009: 113: 726-32.
33. Cooley S, Weisdorf DJ, Guethlein LA et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010: 116: 2411-9.
34. Venstrom JM, Pittari G, Gooley TA et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012: 367: 805-16.
35. Peruzzi M, Wagtmann N, Long EO. A p70 killer cell inhibitory receptor specific for several HLA-B allotypes discriminates among peptides bound to HLA-B*2705. J Exp Med 1996: 184: 1585-90.
36. Rajagopalan S, Long EO. The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide selectivity. J Exp Med 1997: 185: 1523-8.
37. Boyington JC, Motyka SA, Schuck P, Brooks AG, Sun PD. Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 2000: 405: 537-43.
38. Fan QR, Long EO, Wiley DC. Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat Immunol 2001: 2: 452-60.
39. Baron F, Petersdorf EW, Gooley T et al. What is the role for donor natural killer cells after nonmyeloablative conditioning? Biol Blood Marrow Transplant 2009: 15: 580-8.
40. Wu CJ, Yang XF, McLaughlin S et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000: 106: 705-14.
41. Bellucci R, Alyea EP, Chiaretti S et al. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood 2005: 105: 3945-50.
42. Bray RA, Hurley CK, Kamani NR et al. National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. Biol Blood Marrow Transplant 2008: 14: 45-53.
43. Kawase T, Morishima Y, Matsuo K et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 2007: 110: 2235-41.
44. Shaw BE, Gooley TA, Malkki M et al. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood 2007: 110: 4560-6.
45. Fleischhauer K, Shaw BE, Gooley T et al. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol 2012: 13: 366-74.
46. Kawase T, Matsuo K, Kashiwase K et al. HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood 2009: 113: 2851-8.
47. Shaw BE, Mayor NP, Russell NH et al. Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia 2010: 24: 58-65.
48. Anasetti C, Logan BR, Lee SJ et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012: 367: 1487-96.
49. Deeg HJ, Spitzer TR, Cottler-Fox M, Cahill R, Pickle LW. Conditioning-related toxicity and acute graft-versus-host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant 1991: 7: 193-8.
50. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991: 77: 1660-5.
51. Mielcarek M, Martin PJ, Leisenring W et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003: 102: 756-62.
52. Rotta M, Storer BE, Storb R et al. Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010: 16: 1463-6.
53. Rotta M, Storer BE, Storb RF et al. Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood 2010: 115: 1288-95.
54. Deeg HJ, Storer BE, Boeckh M et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006: 12: 573-84.
55. Soiffer RJ, Lerademacher J, Ho V et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011: 117: 6963-70.
56. Bashey A, Medina B, Corringham S et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009: 113: 1581-8.
57. Zhou J, Bashey A, Zhong R et al. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant 2011: 17: 682-92.
58. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012: 366: 2443-54.
59. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012: 366: 2455-65.
60. Maury S, Lemoine FM, Hicheri Y et al. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation. Sci Transl Med 2010: 2: 41-52.
61. Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995: 345: 1016-20.
62. Cabrera R, Diaz-Espada F, Barrios Y et al. Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma. Bone Marrow Transplant 2000: 25: 1105-8.
63. Neelapu SS, Munshi NC, Jagannath S et al. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant 2005: 36: 315-23.
64. Sergeeva A, Alatrash G, He H et al. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 2011: 117: 4262-72.
65. Rousseau RF, Biagi E, Dutour A et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood 2006: 107: 1332-41.
66. Ho VT, Vanneman M, Kim H et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A 2009: 106: 15825-30.
67. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992: 257: 238-41.
68. Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995: 345: 9-13.
69. Leen AM, Myers GD, Sili U et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006: 12: 1160-6.
70. Hanley PJ, Cruz CR, Savoldo B et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009: 114: 1958-67.
71. Heemskerk MH, Hoogeboom M, Hagedoorn R, Kester MG, Willemze R, Falkenburg JH. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 2004: 199: 885-94.
72. Cooper LJ, Al-Kadhimi Z, Serrano LM et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood 2005: 105: 1622-31.
73. Micklethwaite KP, Savoldo B, Hanley PJ et al. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood 2010: 115: 2695-703.
74. Kochenderfer JN, Wilson WH, Janik JE et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010: 116: 4099-102.
75. Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011: 121: 1822-6.
76. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011: 365: 725-33.
77. Brentjens RJ, Riviere I, Park JH et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011: 118: 4817-28.
78. Kochenderfer JN, Dudley ME, Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012: 119: 2709-20.
79. Kochenderfer JN, Dudley ME, Maric I et al. Dramatic regression of chronic lymphocytic leukemia in the first patient treated with donor-derived genetically-engineered anti-CD19-chimeric-antigen-receptor-expressing T cells after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011: 17: S158.
80. Provasi E, Genovese P, Lombardo A et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 2012: 18: 807-15.